Article Text

AB0585 Clinical Characterization of Cutaneous Single-Organ Vasculitis According to Chapel Hill-2012 Criteria. Study of 60 Patients from A Series of 766 Cutaneous Vasculitis
  1. J. Loricera1,
  2. R. Blanco1,
  3. T. Pina1,
  4. V. Calvo-Río1,
  5. F. Ortiz-Sanjuán1,
  6. M. Santos-Gόmez1,
  7. J. Rueda-Gotor1,
  8. L. Άlvarez2,
  9. M.C. González-Vela3,
  10. M.A. González-Lόpez4,
  11. S. Armesto4,
  12. M. Marcellán4,
  13. M.A. González-Gay1
  1. 1Rheumatology
  2. 2Pediatrics
  3. 3Pathology
  4. 4Dermatology, Hospital Universitario Marqués De Valdecilla, Santander, Spain


Background Cutaneous vasculitis (CV) encompasses a wide group of entities characterized by skin blood vessels inflammation. Cutaneous single-organ vasculitis (CSOV) was recently defined according to Chapel Hill-2012 criteria as a CV limited to skin. To our knowledge, there is not any published report on CSOV.

Objectives Our aim was to characterize CSOV from a wide series of CV.

Methods We study CSOV from a series of 766 patients with CV from a single university center. CSOV was diagnosed according to Chapel Hill-2012 criteria. The following conditions were required: a) a skin biopsy showing characteristic leukocytoclastic vasculitis and b) vasculitis limited to skin.

Results We study 60 patients (26 women and 34 men) with a mean age ± SD of 55.70±16.25 years who fulfilled the Chapel Hill-2012 definition for CSOV. The main precipitating events were drug intake (26 patients, 52%) and a previous infection (17 patients, 34%). The main clinical manifestations were cutaneous (100%, palpable purpura in 81.7%) and fever (11 cases, 18.33%). The analytical findings were leukocytosis (mean; 13009±1082x109/L) and elevated ESR (mean, 40.2±22.7 mm/1st hour). In most patients pharmacological therapies were not required (73.33%). In the remaining patients the drugs used were nonsteroidal anti-inflammatory drugs (13.3%), corticosteroids (15%), antihistaminic drugs (3.3%) and colchicine (1,7%). After a median follow-up of 4 months [IQR:2-13] a complete recovery was observed in all the cases and relapses were observed in 5 (8.3%) patients.

Conclusions CSVO according to Chapel Hill-2012 criteria is a benign syndrome.

Acknowledgements This study was supported by a grant from “Fondo de Investigaciones Sanitarias” PI12/00193 (Spain). This work was also partially supported by RETICS Programs, RD08/0075 (RIER) and RD12/0009/0013 from “Instituto de Salud Carlos III” (ISCIII) (Spain).

Disclosure of Interest None declared

DOI 10.1136/annrheumdis-2014-eular.2706

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.